← Russell 3000 cross-section

CYRX Cryoport, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$848m
Revenue TTM
$186m
Net income TTM
$-34m
Free cash flow
$-20m
Composite score
52.4
Sector rank
#2118

Valuation

P / E
EV / EBITDA
EV / sales
2.4
FCF yield
-2.36%
Earnings yield vs 10-yr
-8.71pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-18.1%
EBITDA margin
-6.2%
ROE
-6.9%
ROIC
-39.7%
Revenue growth
-8.0%

Insider activity, last 90 days

Net open-market
$-4.05m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Revenue from this reportable segment is primarily comprised of Life Sciences Services revenue and includes certain immaterial revenue from the sale of accessories that constitute Life Sciences Products revenue. See Note 16 – Segment Reporting in our accompanying condensed consolidated financial statements for additional information about our segments. Results of Operations Three months ended June 30, 2026 compared to three months ended June 30, 2025: The following table summarizes certain information derived from our unaudited condensed consolidated statements of operations (in thousands): ​ ​ ​ Total revenue by type (in thousands): ​ ​ Revenue . …Cryoport, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →